December 26, 2023 11:52 AM EST

Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti

Nicole DeFeudis

Editor

The FDA has added a black box warning to Johnson & Johnson and Legend Biotech’s CAR-T treatment Carvykti as the agency continues to investigate rare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti

Nicole DeFeudis

Editor

Sign up to read this article for free.

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CagriSema’s weight loss data disappointed. What does Novo do next?

Fol­low­ing FDA in­quiry in­to CAR-T safe­ty, agency adds warn­ing on sec­ondary can­cers for Carvyk­ti

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CagriSema’s weight loss data disappointed. What does Novo do next?